Preliminary Agenda Announced for Circulating Tumor Cells at Molecular Medicine Tri-Conference

BOSTON - Sept. 10, 2014 - PRLog -- DATE – Needham, MA – Cambridge Healthtech Institute announces the preliminary agenda for Circulating Tumor Cells at the 22^nd International Molecular Medicine Tri-Conference, which is taking place February 15-20, 2015 at Msocone North Convention Center in San Francisco.

Circulating biomarkers continue to dominate cancer research by detecting the elusive signature in blood, serum or plasma. Isolation and characterization of circulating tumor cells and cell-free DNA enable the precise diagnosis and monitoring of cancer but significant challenges remain in validating methods for clinical use. This conference will showcase advances in technology and clinical applications and ultimately decide which will be the most robust technologies for personalized cancer care.

The Tri-Conference is the industry's Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology. Spanning six days this year, the Tri-Conference includes an expanded program that includes 6 symposia, over 20 short courses, and 17 conference programs.

full program agenda and registration information can be accessed online at http://www.triconference.com/

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI), founded in 1992, is the industry leader in providing superior-quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett Educational Services, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners Cambridge Healthtech Media Group and Knowledge Foundation.